Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. ADX10059 has already recently demonstrated a potential therapeutic benefit in a Phase IIa study in gastro-esophageal reflux disease (GERD), and is currently completing a Phase IIa study in anxiety.

ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway. Inhibition of mGluR5 might therefore prevent the initiation of the migraine circuit, or interrupt it once established. For this initial exploratory study on the utility of an mGluR5 NAM in the management of migraine, an acute treatment paradigm was used.

The study was conducted in 129 migraine patients at opinion leader sites in the UK and Germany, according to the gold-standard design used for acute treatment of migraine. It comprised a multi-centre, double-blind, placebo-controlled comparison of a single dose of ADX10059 with placebo, to treat a single moderate or severe (IHS Grade 2 or 3) migraine headache, in an outpatient setting. Standard efficacy outcomes were used, with the primary efficacy variable being the proportion of patients pain-free (IHS Grade 0) 2 hours after dosing.

ADX10059 met the primary endpoint, showing a statistically significant higher number of patients pain-free 2 hours after dosing compared to placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

Post Your Comments:
(Date:12/1/2009)...RK, Dec. 1 Reportlinker.com announ... in its catalogue: ,, Medical Oxygen Systems ...reportlinker.com/p0164334/Medical-Oxygen-Systems--... medical oxygen systems market for home healthcare...s. The buoyant growth expectations stem from demog...
(Date:12/1/2009)...N.J., Dec. 1 Johnson & Johnson... announced today that it has submitted a New Drug ...stration (FDA) for tapentadol extended release (ER...he management of moderate to severe chronic pain i...c pain, defined as pain that persists for long per...
(Date:12/1/2009)...STATION, N.J., Dec. 1 Merck & ...rug Administration (FDA) has approved ZEGERID OTC(...apsules), for over-the-counter treatment of freque...he-counter by Schering-Plough HealthCare Products,...amp; Co., Inc. Schering-Plough and Merck merged on...
Breaking Medicine Technology:Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 3New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 5New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 7FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4Interventional radiology resources cover peripheral arterial disease 56584 1Interventional radiology resources cover peripheral arterial disease 56584 2Interventional radiology resources cover peripheral arterial disease 56584 3Toward a nanomedicine for brain cancer 9839 1ACLA Opposes Proposed LabTax 56582 1ACLA Opposes Proposed LabTax 56582 2
... by Medical Research Council, LEXINGTON, Mass., A...EV ) announced today the completion of,enrollment ... PRO 2000, the,Company,s candidate vaginal microbi...transmitted infections. The trial is sponsored by ...) and conducted by the Microbicides,Development Pr...
...ciences, Inc. (Nasdaq: HGSI ) today announced tha...ng of patients in a randomized Phase 2 trial of,HG...therapy agents,paclitaxel and carboplatin as first...er (NSCLC)., (Logo: http://www.newscom.com/cgi-b...medical need for effective treatment options for,n...
Other Medicine Technology:Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 2Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 4Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 5
(Date:12/2/2009)...e, many more to come, NIH director says, , ...een stem cell lines have been added to the pool th..., and many more such lines will soon be made avail..., These are the first additional embryonic stem .... National Institutes of Health (NIH) since Presid...
(Date:12/2/2009).... 2 In the wake of the ...minated with a plastics chemical linked to birth d...ately to protect infants and mothers. ,, The Ho...nol A, or BPA, in food and beverage containers. Th...d Rep. Edward Markey of Massachusetts, would prote...
(Date:12/2/2009).../PRNewswire/ - As part of its continued commitment... part of Pfizer, has pledged more than 40 million ...o the World Federation of Hemophilia (WFH). This i...nitarian Aid Program, and will make a significant ...ation will directly support building sustainable n...
(Date:12/2/2009)...y federal government ends nine months of obstructi...RNewswire-USNewswire/ -- More than 2,300 healthcar...ilities across Southern California will soon vote ...Healthcare Workers (NUHW). ,, A majority of the... but SEIU delayed the election by filing frivolous...
(Date:12/2/2009)...oves sports. An avid tennis player and golfer, as ...ent became increasingly frustrated over time as hi...ve eye disorder. Unable to return the tennis ball ...ospect of a corneal transplant to restore his visi...oni discovered an alternative treatment. He receiv...
Breaking Medicine News(10 mins):Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
...A mysterious post-operative eye ailment that swept...the cataract-surgery unit in Scarborough Hospital,...ek. // The Hospital, which performs around 5,0...nown as toxic anterior segment syndrome, or TASS. ...
...People working at call centres could suffer hearin...// Acoustic shocks are temporary or permanen... the nervous system, which may be caused to the us...cted noise. Two thirds of call centres in Britain ...
...Last May, two animal caretakers sent letters to ci.... government lab's disposal procedures were not st...at died of infectious diseases such as mad cow and...cials to study the issue at length. The eight-pers...
...A New Zealand woman who travelled to China for ste...s of her husband, Rein. She was 66. // Willie...or neurone disease in 2004.She left her home in Ro...y that aids speaking, breathing and swallowing. ...
...Patients with dementia have been benefited by occu... perform tasks around the house thereby //improvin...o recent research. Dementia such as Alzheimer'...es, current drugs do not improve the symptoms of d...
...An alert over potential outbreak of 'Legionnaires ...r 500 guests who visited the Grand Atlantic Hotel ...by the health officials after water samples tested...nnaires disease is caused by the bacterium Legione...
Other Medicine News:Health News:Eye Surgeries Remain Cancelled Due To TASS Outbreak In Toronto 2Health News:Complaints Against US Federal lab Over-ruled by Panel 2Health News:Task therapy Beneficial to Patients with Dementia 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: